CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Active, not recruiting · NCT04176848 · Registry updated 2026-02-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-02-18 | NCT04176848 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Canadian Cancer Trials Group | 73 |
| University Health Network, Toronto | 417 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BCCA - Cancer Centre for the Southern Interior | Kelowna | Canada | 4 |
| Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton | Canada | 60 |
| Kingston Health Sciences Centre | Kingston | Canada | 91 |
| Ottawa Hospital Research Institute | Ottawa | Canada | 46 |
| University Health Network | Toronto | Canada | 52 |